TB-500 Animal Study Doses vs. Human Protocols: Understanding the mg/kg Gap

Q: Can I use the allometric scaling formula to calculate my own TB-500 dose?

The formula itself is real, publicly documented FDA methodology, but applying it to produce a specific personal dose is not something it was designed to do or something any study has validated for TB-500 research-chemical use. It requires choosing which animal study to scale from, and it was built to estimate a conservative starting point for a monitored clinical trial, not an optimal dose for unsupervised use.

Q: Why do animal studies use such different doses from each other?

Because they answer different questions. A topical wound-healing study uses microgram quantities applied directly to the wound, while a systemic brain-injury study uses milligrams per kilogram given intraperitoneally. The dose reflects the study's specific model and endpoint, not a single correct dose that varies by mistake between papers.

Q: Is the human trial dose data relevant to TB-500 research-chemical protocols?

Only as context. That data comes from RGN-352, an IV formulation of full-length thymosin beta-4 studied for cardiac indications in a regulated, medically monitored trial, a different molecule, route, and clinical context from the subcutaneously injected synthetic fragment sold as TB-500. It is not a translatable reference point.

Q: Does this mean animal research on TB-500 isn't useful?

No, it means animal research serves a different purpose than dosing. It establishes mechanism, plausibility, and biological effect in a controlled model. It was never designed to hand researchers a validated human dose, and reading it that way overstates what the studies were built to show.

> Research disclaimer: This article explains a regulatory dose-conversion methodology and summarizes published dose figures from animal and human clinical research, for informational and research-literacy purposes only. It is not a dosing recommendation, does not endorse any specific dose, and is not medical advice. TB-500 is sold as a research chemical and is not FDA-approved for human use.

Why Animal Study Doses Don't Just Translate to Human Protocols

Quick answer: Published thymosin beta-4 (Tβ4) animal studies report doses in mg/kg body weight — figures like 5–6 mg/kg in rats — that cannot be applied to a human by simply multiplying by body weight. Regulatory science uses a specific conversion method called allometric scaling, based on body surface area rather than weight alone, to estimate a human equivalent dose (HED) from an animal dose. Even that formal conversion has real limits when applied to TB-500 research-chemical use, because it was designed for estimating safe starting doses in regulated drug trials, not for reverse-engineering a research protocol from rodent data.

Our common research mistakes guide flags "overgeneralizing from animal or preclinical data" as a recurring error. This article is the fuller breakdown of what that overgeneralization actually looks like in the numbers, and what the more careful conversion method does and doesn't tell you.

---

What Animal Studies Actually Used

Published Tβ4 research reports a range of doses and administration routes depending on the model and tissue being studied. A few representative examples from the published literature:

| Study context | Species | Dose | Route |
|---|---|---|---|
| Traumatic brain injury | Rat | 6 mg/kg | Intraperitoneal, day 1 then every 3 days × 4 more doses |
| Skin flap survival | Rat | 5 mg/kg, twice daily | Intraperitoneal |
| Dermal punch wound healing | Rat | 5 μg per 50 μL PBS | Topical/local, applied to wound |
| Dermal wound healing (systemic) | Rat | 60 μg per 300 μL | Intraperitoneal, days 0, 2, 4, 6 |
| Muscular dystrophy model | Mouse (mdx) | 150 μg, twice weekly | Subcutaneous, over 6 months |

Two things stand out immediately. First, the doses aren't consistent even within animal research — a wound-healing model using micrograms applied locally is a completely different order of magnitude from a brain-injury model using milligrams per kilogram systemically, because the research questions themselves are different. Second, the vehicle in nearly all of this research is phosphate-buffered saline (PBS) or a comparable sterile physiological buffer, delivered by intraperitoneal or topical application — not bacteriostatic water delivered by subcutaneous injection, which is the standard community reconstitution and administration method covered in our reconstitution guide and bacteriostatic vs. sterile water guide. PBS is a research-lab formulation vehicle, not a diluent used outside laboratory settings.

What the Limited Human Dose Data Shows

This site's human clinical trials guide covers RGN-259, RegeneRx's ophthalmic eye-drop formulation of full-length Tβ4 — a different molecule, route, and indication from the injectable fragment sold as TB-500. There's a separate, less-discussed human dose history worth adding to that picture: RegeneRx also developed RGN-352, an intravenous formulation of Tβ4 studied for cardiac indications.

A Phase 1 IV safety trial evaluated doses across a 42 mg to 1,260 mg range over 14 days, reported as safe and well tolerated with no dose-limiting toxicity.

A subsequent Phase 2 trial in acute myocardial infarction patients was designed around 450 mg and 1,200 mg doses, administered by IV push daily for the first three days and then weekly for four additional weeks.

Both figures are worth sitting with for a moment, because they're dramatically larger than typical community TB-500 doses, which are usually discussed in single-digit milligrams per week. The gap isn't a sign that community dosing is arbitrary — it reflects that RGN-352 is a different formulation (full-length, 43-amino-acid Tβ4 rather than the shorter synthetic fragment sold as TB-500), given by a different route (IV rather than subcutaneous), for a different indication (acute cardiac injury rather than general tissue-repair research), in a regulated trial with medical monitoring. None of those conditions carry over to a self-administered research-chemical protocol, which is exactly why this figure can't be used as a target or a ceiling for anything else.

---

How Regulatory Science Converts Animal Doses to Human Equivalents

When developing a new compound, researchers need a starting point for how much of it might be reasonable to test in a first human trial. Simply scaling by body weight overstates the appropriate human dose, because smaller animals have a higher metabolic rate relative to their body weight than larger ones. The FDA's guidance for estimating safe starting doses instead uses allometric scaling, based on body surface area, via a standardized set of correction factors called Km factors.

The formula:

> Human Equivalent Dose (mg/kg) = Animal Dose (mg/kg) × (Animal Km ÷ Human Km)

Standard Km factors:

| Species | Km factor |
|---|---|
| Mouse | 3 |
| Rat | 6 |
| Human | 37 |

Worked example: A 10 mg/kg mouse dose converts to a human equivalent of 10 × (3 ÷ 37) ≈ 0.81 mg/kg — roughly 57 mg for a 70 kg adult, not the 700 mg a simple weight-based multiplication would suggest. Applying the same formula to the 6 mg/kg rat TBI dose above: 6 × (6 ÷ 37) ≈ 0.97 mg/kg, or roughly 68 mg for a 70 kg adult.

That "roughly 68 mg" figure is worth comparing to the Phase 1 RGN-352 human trial range of 42–1,260 mg described above — it lands well inside that range, which is a useful sanity check on the method (regulatory dose-scaling and an actual regulated trial arrived at broadly comparable orders of magnitude), even though, again, that trial used a different molecule, route, and clinical context entirely.

Why This Formula Doesn't Solve TB-500 Dosing

Allometric scaling is a genuine, widely used regulatory tool — but understanding what it was built to do clarifies why it doesn't function as a dosing calculator for TB-500 research-chemical use:

It was designed to estimate a safe starting dose for a first-in-human trial, with a built-in safety margin and clinical oversight, not to identify an effective or optimal dose for any purpose.

It doesn't account for route of administration. Every animal dose in the table above used intraperitoneal, topical, or subcutaneous delivery in a controlled lab setting; the human trial data used IV. Bioavailability differs by route, and the scaling formula doesn't correct for that on its own.

It doesn't account for what the dose is trying to achieve. A brain-injury dose, a wound-healing dose, and a cardiac-injury dose are answering different research questions in the underlying studies; there's no single "the" animal dose to scale from TB-500 research as a whole.

No study has scaled community TB-500 use against any of this data and validated the result against an outcome. The math above is real and directly attributable to FDA methodology and the animal figures are real published numbers, but connecting the two to a specific human research-chemical dose is not something any published study has done.

Our dosage protocol guide covers how community-derived protocols are actually structured, which — it's worth being direct — is not by working backward through this formula. Community dosing conventions developed independently of this calculation, through shared anecdotal practice rather than derived from the allometric method described here.

---

What This Is Useful For (and What It Isn't)

Understanding allometric scaling is useful for reading TB-500 research literature critically — recognizing that a headline like "6 mg/kg reduced brain injury markers in rats" describes a specific, non-transferable number, and knowing the general math that connects animal and human dose ranges when regulatory bodies do that conversion formally. It's not useful as a way to calculate a personal research dose, because the inputs (which study, which route, which endpoint) don't collapse into a single answer, and because the formula's entire purpose is a conservative starting estimate for a monitored clinical trial — a context that doesn't exist for self-directed research-chemical use.

---

Frequently Asked Questions

Can I use the allometric scaling formula to calculate my own TB-500 dose?

The formula itself is real and publicly documented FDA methodology, but applying it to produce a specific personal dose isn't something the formula was designed to do or something any study has validated for TB-500 research-chemical use. It requires choosing which animal study to scale from, none of which represents "the" TB-500 dose, and it was built to estimate a conservative starting point for a monitored clinical trial, not an optimal or effective dose for unsupervised use.

Why do animal studies use such different doses from each other?

Because they're answering different questions. A topical wound-healing study measuring local tissue response uses microgram quantities applied directly to the wound; a systemic brain-injury study measuring circulating drug effect uses milligrams per kilogram given intraperitoneally. The dose reflects the study's specific model and endpoint, not a single "correct" Tβ4 dose that varies by mistake between papers.

Is the human trial dose data (42–1,260 mg) relevant to TB-500 research-chemical protocols?

Only as context, not as a benchmark. That data comes from RGN-352, an IV formulation of full-length Tβ4 studied for cardiac indications in a regulated, medically monitored trial — a different molecule, route, and clinical context from the subcutaneously injected synthetic fragment sold as TB-500. The scale of the numbers is informative for understanding how far apart regulated trial dosing and community research-chemical dosing are; it isn't a translatable reference point.

What's the biggest mistake researchers make when reading animal dose data?

Treating a single animal study's mg/kg figure as if it converts directly to a human dose by simple weight ratio. That overstates the appropriate human amount, because smaller animals metabolize compounds faster relative to body weight than humans do. Even the more accurate body-surface-area method (allometric scaling) is a regulatory starting-dose estimate, not a precision calculation applicable to any specific protocol.

Does this mean animal research on TB-500 isn't useful?

No — it means animal research is useful for a different purpose than dosing. It establishes mechanism, plausibility, and biological effect in a controlled model, which is what most of this site's tissue- and condition-specific research guides describe. It was never designed to hand researchers a validated human dose, and reading it that way overstates what the studies were built to show.

Sourcing Note

Dose-conversion math is only as meaningful as the compound it's applied to. Apollo Peptide Sciences publishes third-party HPLC testing and certificates of analysis for its TB-500, which at minimum confirms what's in the vial before any dosing question — scaled from animal data or otherwise — becomes relevant.

---